DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy Drugs – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for Duchenne Muscular Dystrophy Drugs, valued at US$2 billion in 2022, is projected to grow to US$27.4 billion by 2030, with a remarkable compound annual growth rate (CAGR) of 39.1% during the analysis period of 2022-2030.
Among the segments analyzed in the report, Exon Skipping is expected to lead the growth with a CAGR of 44.9%, reaching US$18.1 billion by the end of the forecast period. The Steroid Therapy segment is estimated to grow at a CAGR of 27.7% over the next 8 years.
Key Market Insights:
- The U.S. Duchenne Muscular Dystrophy Drugs market is estimated at US$843.1 million in 2022.
- China, the world’s second-largest economy, is forecasted to reach a market size of US$2.4 billion by 2030, with a CAGR of 46%.
- Japan and Canada are also noteworthy markets, expected to grow at 32.6% and 31.7% respectively from 2022 to 2030.
- Within Europe, Germany is forecasted to grow at approximately 34.8% CAGR.
Select Competitors:
Key players in the Duchenne Muscular Dystrophy Drugs market include:
- Acceleron Pharma, Inc.
- Akashi Therapeutics, Inc.
- BioMarin Pharmaceutical, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Janssen Pharmaceuticals, Inc.
- Lexicon Pharmaceuticals, Inc.
- Nippon Shokubai Co., Ltd.
- Nobelpharma Co., Ltd.
- Pfizer, Inc.
- PTC Therapeutics, Inc.
- Sarepta Therapeutics Inc.
- Taiho Pharmaceutical Co., Ltd.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 220 |
| Forecast Period | 2022 – 2030 |
| Estimated Market Value (USD) in 2022 | $2 Billion |
| Forecasted Market Value (USD) by 2030 | $27.4 Billion |
| Compound Annual Growth Rate | 38.7% |
| Regions Covered | Global |
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- A Prelude to Duchenne Muscular Dystrophy
- Global Economic Update
- From Pandemic to War & Inflation: “Gloomy Outlook for 2023 Despite Signs of Easing Inflationary Conditions
- Here’s How Inflationary Pressures Affect the Economy
- Here’s What’s Causing Inflationary Pressures in the Global Market
- Although Past Peak in 2023, Efforts to Solve the Inflation Puzzle Should Continue
- Global Economy Faces a Tough Climb Towards Recovery Made Rockier by the War, Anti-Inflation Fiscal Policies & Slower Than Desirable Easing of Inflationary Pressures: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
- Impact of COVID-19 on Duchenne Muscular Dystrophy Drugs Market
- Competition
- Product Development as Hallmark of Global Duchenne Muscular Dystrophy Market
- Duchenne Muscular Dystrophy Drugs – Global Key Competitors Percentage Market Share in 2023 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
- Global Market Overview and Prospects
- Global Duchenne Muscular Dystrophy Drugs Market Set for a Rapid Growth, Driven by Rising Prevalence
- A Review of the Approved DMD Drugs
- North America and Europe to Remain Lucrative Markets
- Molecular Therapy, Hospital/Clinic & Hospital Pharmacy: Hale & Hearty Segments of Duchenne Muscular Dystrophy Market
- Dynamic Factors Keeping Duchenne Muscular Dystrophy Market Growing
- Market Drivers
- Rising Incidence of DMD to Catalyze Growth
- DMD Prevalence (in 100,000 Population) in Select Countries: 2020
- High Uptake of Novel Therapies & Drugs
- Market Restraints & Challenges
- Lack of Standardization for Clinical Efficacy
- Stringent Regulatory Regime
- Market Opportunities
- Product Developments & Rising Awareness
- Surge in Clinical Trials to Launch Novel Options
- Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising R&D Investment to Boost DMD Market
- Select Therapy Candidates Under Development for Treating DMD
- Growing Government Support Propels Market Expansion
- Biologics – The Most Dynamic Segment of the Market
- Blossoming of Gene Therapy in Duchenne Muscular Dystrophy Treatment Domain
- Gene Therapy for DMD Treatment
- Elevidys, The First Ground-breaking Gene Therapy for Treatment of Duchenne Muscular Dystrophy (DMD)
- Children’s National Hospital Starts Offering Newly Approved Gene Therapy for DMD
- Promising Gene Therapies
- Potential Side-Effects & Risks of Gene Therapies
- Vamorolon Holds Potential to Lessen Health Risks Linked with Extended Use of Steriods
- DT-DEC01 Offers Promise to Stabilize or Improve Motor Function
- AOC 1044 Receives Orphan Drug Status for DMD44
- Italfarmaco Group Announces NDA Acceptance for Givinostat Targeting Duchenne Muscular Dystrophy
- Uptrend in Healthcare Expenditure Creates Substantial Opportunities
- World Healthcare Expenditure (In US$ Trillion) for the Years 2019, 2021 & 2023
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/5u5apo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900